Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2011
Targeting superficial or nodular Basal cell carcinoma with topically formulated small molecule inhibitor of smoothenedTracy Tang, Jean Y Tang, Dongwei Li, et al.
Nature|December 25, 2015
Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell functionElaine E Storm, Steffen Durinck, Felipe de Sousa e Melo, et al.
Communications Medicine|May 16, 2024
Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACsDonglu Zhang, Bin Ma, Peter S Dragovich, et al.
Science (New York, N.Y.)|September 4, 2009
Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastomaRobert L Yauch, Gerrit J P Dijkgraaf, Bruno Alicke, et al.
The New England Journal of Medicine|September 4, 2009
Inhibition of the hedgehog pathway in advanced basal-cell carcinomaDaniel D Von Hoff, Patricia M LoRusso, Charles M Rudin, et al.
NPJ Precision Oncology|June 7, 2018
A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer typesMarie-Claire Wagle, Daniel Kirouac, Christiaan Klijn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancerDavid R Spigel, Thomas J Ervin, Rodryg A Ramlau, et al.
The New England Journal of Medicine|June 8, 2012
Efficacy and safety of vismodegib in advanced basal-cell carcinomaAleksandar Sekulic, Michael R Migden, Anthony E Oro, et al.
Cancer Cell|March 12, 2015
Genomic analysis of smoothened inhibitor resistance in basal cell carcinomaHayley J Sharpe, Gregoire Pau, Gerrit J Dijkgraaf, et al.
Pageof 6